These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

634 related articles for article (PubMed ID: 9038338)

  • 21. Chromatin-dependent allosteric regulation of DNMT3A activity by MeCP2.
    Rajavelu A; Lungu C; Emperle M; Dukatz M; Bröhm A; Broche J; Hanelt I; Parsa E; Schiffers S; Karnik R; Meissner A; Carell T; Rathert P; Jurkowska RZ; Jeltsch A
    Nucleic Acids Res; 2018 Sep; 46(17):9044-9056. PubMed ID: 30102379
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heterogeneity in the modification and involvement of chromatin components of the CpG island of the silenced human CDH1 gene in cancer cells.
    Koizume S; Tachibana K; Sekiya T; Hirohashi S; Shiraishi M
    Nucleic Acids Res; 2002 Nov; 30(21):4770-80. PubMed ID: 12409468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A mutant form of MeCP2 protein associated with human Rett syndrome cannot be displaced from methylated DNA by notch in Xenopus embryos.
    Stancheva I; Collins AL; Van den Veyver IB; Zoghbi H; Meehan RR
    Mol Cell; 2003 Aug; 12(2):425-35. PubMed ID: 14536082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MeCP2 binds cooperatively to its substrate and competes with histone H1 for chromatin binding sites.
    Ghosh RP; Horowitz-Scherer RA; Nikitina T; Shlyakhtenko LS; Woodcock CL
    Mol Cell Biol; 2010 Oct; 30(19):4656-70. PubMed ID: 20679481
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chromosomal regulation by MeCP2: structural and enzymatic considerations.
    Bowen NJ; Palmer MB; Wade PA
    Cell Mol Life Sci; 2004 Sep; 61(17):2163-7. PubMed ID: 15338046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MeCP2 preferentially binds to methylated linker DNA in the absence of the terminal tail of histone H3 and independently of histone acetylation.
    Ishibashi T; Thambirajah AA; Ausió J
    FEBS Lett; 2008 Apr; 582(7):1157-62. PubMed ID: 18339321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methylation-dependent silencing at the H19 imprinting control region by MeCP2.
    Drewell RA; Goddard CJ; Thomas JO; Surani MA
    Nucleic Acids Res; 2002 Mar; 30(5):1139-44. PubMed ID: 11861904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulation of transcription and chromatin by methyl-CpG binding protein MBD1.
    Nakao M; Matsui S; Yamamoto S; Okumura K; Shirakawa M; Fujita N
    Brain Dev; 2001 Dec; 23 Suppl 1():S174-6. PubMed ID: 11738867
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Methyl-CpG binding domain proteins and their involvement in the regulation of the MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A12 gene promoters.
    Wischnewski F; Friese O; Pantel K; Schwarzenbach H
    Mol Cancer Res; 2007 Jul; 5(7):749-59. PubMed ID: 17634428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular biology. MeCP2 repression goes nonglobal.
    Klose R; Bird A
    Science; 2003 Oct; 302(5646):793-5. PubMed ID: 14593157
    [No Abstract]   [Full Text] [Related]  

  • 31. Functional consequences of Rett syndrome mutations on human MeCP2.
    Yusufzai TM; Wolffe AP
    Nucleic Acids Res; 2000 Nov; 28(21):4172-9. PubMed ID: 11058114
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The solution structure of the domain from MeCP2 that binds to methylated DNA.
    Wakefield RI; Smith BO; Nan X; Free A; Soteriou A; Uhrin D; Bird AP; Barlow PN
    J Mol Biol; 1999 Sep; 291(5):1055-65. PubMed ID: 10518942
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biochemical analysis of histone deacetylase-independent transcriptional repression by MeCP2.
    Theisen JW; Gucwa JS; Yusufzai T; Khuong MT; Kadonaga JT
    J Biol Chem; 2013 Mar; 288(10):7096-104. PubMed ID: 23349465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Visualization and 3D structure determination of defined sequence chromatin and chromatin remodeling complexes.
    Horowitz-Scherer RA; Woodcock CL
    Methods Enzymol; 2004; 376():29-48. PubMed ID: 14975297
    [No Abstract]   [Full Text] [Related]  

  • 35. Methyl CpG-binding proteins induce large-scale chromatin reorganization during terminal differentiation.
    Brero A; Easwaran HP; Nowak D; Grunewald I; Cremer T; Leonhardt H; Cardoso MC
    J Cell Biol; 2005 Jun; 169(5):733-43. PubMed ID: 15939760
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heterogeneity in residual function of MeCP2 carrying missense mutations in the methyl CpG binding domain.
    Kudo S; Nomura Y; Segawa M; Fujita N; Nakao M; Schanen C; Tamura M
    J Med Genet; 2003 Jul; 40(7):487-93. PubMed ID: 12843318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rett syndrome: a surprising result of mutation in MECP2.
    Dragich J; Houwink-Manville I; Schanen C
    Hum Mol Genet; 2000 Oct; 9(16):2365-75. PubMed ID: 11005791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MeCP2 binds to nucleosome free (linker DNA) regions and to H3K9/H3K27 methylated nucleosomes in the brain.
    Thambirajah AA; Ng MK; Frehlick LJ; Li A; Serpa JJ; Petrotchenko EV; Silva-Moreno B; Missiaen KK; Borchers CH; Adam Hall J; Mackie R; Lutz F; Gowen BE; Hendzel M; Georgel PT; Ausió J
    Nucleic Acids Res; 2012 Apr; 40(7):2884-97. PubMed ID: 22144686
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Solution structure of the methyl-CpG binding domain of human MBD1 in complex with methylated DNA.
    Ohki I; Shimotake N; Fujita N; Jee J; Ikegami T; Nakao M; Shirakawa M
    Cell; 2001 May; 105(4):487-97. PubMed ID: 11371345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DNA binding selectivity of MeCP2 due to a requirement for A/T sequences adjacent to methyl-CpG.
    Klose RJ; Sarraf SA; Schmiedeberg L; McDermott SM; Stancheva I; Bird AP
    Mol Cell; 2005 Sep; 19(5):667-78. PubMed ID: 16137622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.